Evidence map›Paper›PMID 34060209›Full record

ArticleDiabetes, obesity & metabolism2021

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.

Vanita R Aroda, Mads Faurby, Søren Lophaven, Josh Noone, Michael Lyng Wolden, Ildiko Lingvay

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. PIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Suitability and Usefulness of a Flexible Dosing Timing of Oral Semaglutide to Maximize Benefit in Clinical Practice: An Expert Panel.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
  15. Efficacy and Safety of Escalating the Dose of Oral Semaglutide from 7 to 14 mg: A Single-Center, Retrospective Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  16. Article
  17. Article
  18. Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Vanita R ArodaDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-7706-4585
Mads FaurbyNovo Nordisk A/S, Søborg, Denmark.
Søren LophavenOmicron ApS, Roskilde, Denmark.
Josh NooneNovo Nordisk, Plainsboro Township, New Jersey, USA.
Michael Lyng WoldenNovo Nordisk A/S, Søborg, Denmark.
Ildiko LingvayDepartment of Internal Medicine/Endocrinology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-7006-7401
Novo Nordisk (Denmark) · DKBrigham and Women's Hospital · USNovo Nordisk (United States) · USRoskilde University · DKThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral semaglutide is the first oral glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and showed significant benefits in glycaemic control and weight reduction versus active comparators in the PIONEER phase 3a randomized controlled trial programme. In this retrospective study, we present early data on the use of oral semaglutide in clinical practice, from the US IBM Explorys electronic health record database. In 782 patients prescribed oral semaglutide, 54.5% were women, and the mean age (SD) was 57.8 years (11.3); 66.0% of patients received their prescription from a primary care practitioner. Although prescribing information recommends increasing the dose to 7 mg after 30 days, 37.0% of patients received a prescription only for the initial 3 mg dose. Mean body mass index was 36.2 kg/m

Indexed as

Diabetes Mellitus, Type 2FemaleGlucagon-Like PeptidesHumansHypoglycemic AgentsMiddle AgedRetrospective StudiesSemaglutideGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideantidiabetic drugdatabase researchGLP-1glycaemic controlobservational studytype 2 diabetes

Identifiers

PMID34060209
PMCPMC8453868
OpenAlexW3164883407

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.